Enzymatic Hydrolysis of Pneumococcal Capsular Polysaccharide Renders the Bacterium Vulnerable to Host Defense

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2018 Jun 6

PMID 29866907

Citations 15

Authors

Dustin R Middleton

Amy V Paschall

Jeremy A Duke

Fikri Y Avci

Affiliations

Soon will be listed here.

Abstract

Despite a century of investigation, remains a major human pathogen, causing a number of diseases, such as pneumonia, meningitis, and otitis media. Like many encapsulated pathogens, the capsular polysaccharide (CPS) of is a critical component for colonization and virulence in mammalian hosts. This study aimed to evaluate the protective role of a glycoside hydrolase, Pn3Pase, targeting the CPS of type 3 , which is one of the most virulent serotypes. We have assessed the ability of Pn3Pase to degrade the capsule on a live type 3 strain. Through assays, we observed that Pn3Pase treatment increases the bacterium's susceptibility to phagocytosis by macrophages and complement-mediated killing by neutrophils. We have demonstrated that Pn3Pase treatment reduces nasopharyngeal colonization and protects mice from sepsis caused by type 3 Due to the increasing shifts in serotype distribution, the rise in drug-resistant strains, and poor immune responses to vaccine-included serotypes, it is necessary to investigate approaches to combat pneumococcal infections. This study evaluates the interaction of pneumococcal CPS with the host at molecular, cellular, and systemic levels and offers an alternative therapeutic approach for diseases caused by through enzymatic hydrolysis of the CPS.

Citing Articles

Immunogenicity and protective efficacy of a prototype pneumococcal bioconjugate vaccine.

Aceil J, Paschall A, Knoot C, Robinson L, Scott N, Feldman M Vaccine. 2022; 40(42):6107-6113.

PMID: 36115800 PMC: 10388713. DOI: 10.1016/j.vaccine.2022.09.018.

Pneumococcal Surface Proteins as Virulence Factors, Immunogens, and Conserved Vaccine Targets.

Aceil J, Avci F Front Cell Infect Microbiol. 2022; 12:832254.

PMID: 35646747 PMC: 9133333. DOI: 10.3389/fcimb.2022.832254.

,-Dimethyldithiocarbamate Elicits Pneumococcal Hypersensitivity to Copper and Macrophage-Mediated Clearance.

Menghani S, Cutcliffe M, Sanchez-Rosario Y, Pok C, Watson A, Neubert M Infect Immun. 2022; 90(4):e0059721.

PMID: 35311543 PMC: 9022595. DOI: 10.1128/iai.00597-21.

Harnessing galactose oxidase in the development of a chemoenzymatic platform for glycoconjugate vaccine design.

Duke J, Paschall A, Glushka J, Lees A, Moremen K, Avci F J Biol Chem. 2021; 298(1):101453.

PMID: 34838818 PMC: 8689215. DOI: 10.1016/j.jbc.2021.101453.

Development and Immunogenicity of a Prototype Multivalent Group B Bioconjugate Vaccine.

Duke J, Paschall A, Robinson L, Knoot C, Vinogradov E, Scott N ACS Infect Dis. 2021; 7(11):3111-3123.

PMID: 34633812 PMC: 8793035. DOI: 10.1021/acsinfecdis.1c00415.

References

Fuchs H, Borowitz D, Christiansen D, Morris E, Nash M, Ramsey B . Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994; 331(10):637-42. DOI: 10.1056/NEJM199409083311003. View

Kim L, McGee L, Tomczyk S, Beall B . Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective. Clin Microbiol Rev. 2016; 29(3):525-52. PMC: 4861989. DOI: 10.1128/CMR.00058-15. View

Metcalf B, Gertz Jr R, Gladstone R, Walker H, Sherwood L, Jackson D . Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect. 2015; 22(1):60.e9-60.e29. PMC: 4721534. DOI: 10.1016/j.cmi.2015.08.027. View

Craig A, Mai J, Cai S, Jeyaseelan S . Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun. 2008; 77(2):568-75. PMC: 2632043. DOI: 10.1128/IAI.00832-08. View

AVERY O, Dubos R . THE PROTECTIVE ACTION OF A SPECIFIC ENZYME AGAINST TYPE III PNEUMOCOCCUS INFECTION IN MICE. J Exp Med. 2009; 54(1):73-89. PMC: 2132045. DOI: 10.1084/jem.54.1.73. View

Bruyn G, Zegers B, Van Furth R . Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis. 1992; 14(1):251-62. DOI: 10.1093/clinids/14.1.251. View

Avci F, Li X, Tsuji M, Kasper D . A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med. 2011; 17(12):1602-9. PMC: 3482454. DOI: 10.1038/nm.2535. View

Kieninger D, Kueper K, Steul K, Juergens C, Ahlers N, Baker S . Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010; 28(25):4192-203. DOI: 10.1016/j.vaccine.2010.04.008. View

Avci F . Novel strategies for development of next-generation glycoconjugate vaccines. Curr Top Med Chem. 2013; 13(20):2535-40. DOI: 10.2174/15680266113136660180. View

10.

Macleod C, HODGES R, Heidelberger M, BERNHARD W . PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES. J Exp Med. 2009; 82(6):445-65. PMC: 2135567. View

11.

Li Y, Metcalf B, Chochua S, Li Z, Gertz Jr R, Walker H . Penicillin-Binding Protein Transpeptidase Signatures for Tracking and Predicting β-Lactam Resistance Levels in Streptococcus pneumoniae. mBio. 2016; 7(3). PMC: 4916381. DOI: 10.1128/mBio.00756-16. View

12.

Middleton D, Zhang X, Wantuch P, Ozdilek A, Liu X, LoPilato R . Identification and characterization of the Streptococcus pneumoniae type 3 capsule-specific glycoside hydrolase of Paenibacillus species 32352. Glycobiology. 2017; 28(2):90-99. PMC: 6192388. DOI: 10.1093/glycob/cwx097. View

13.

Geno K, Gilbert G, Song J, Skovsted I, Klugman K, Jones C . Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev. 2015; 28(3):871-99. PMC: 4475641. DOI: 10.1128/CMR.00024-15. View

14.

Dillard J, Yother J . Genetic and molecular characterization of capsular polysaccharide biosynthesis in Streptococcus pneumoniae type 3. Mol Microbiol. 1994; 12(6):959-72. DOI: 10.1111/j.1365-2958.1994.tb01084.x. View

15.

Bogaert D, de Groot R, Hermans P . Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004; 4(3):144-54. DOI: 10.1016/S1473-3099(04)00938-7. View

16.

Sugimoto N, Yamagishi Y, Hirai J, Sakanashi D, Suematsu H, Nishiyama N . Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review. BMC Res Notes. 2017; 10(1):21. PMC: 5217555. DOI: 10.1186/s13104-016-2353-3. View

17.

Chiavolini D, Pozzi G, Ricci S . Animal models of Streptococcus pneumoniae disease. Clin Microbiol Rev. 2008; 21(4):666-85. PMC: 2570153. DOI: 10.1128/CMR.00012-08. View

18.

Puchta A, Verschoor C, Thurn T, Bowdish D . Characterization of inflammatory responses during intranasal colonization with Streptococcus pneumoniae. J Vis Exp. 2014; (83):e50490. PMC: 4089492. DOI: 10.3791/50490. View

19.

Harboe Z, Dalby T, Weinberger D, Benfield T, Molbak K, Slotved H . Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014; 59(8):1066-73. DOI: 10.1093/cid/ciu524. View

20.

Song J, Moseley M, Burton R, Nahm M . Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013; 19(3):412-25. PMC: 3692352. DOI: 10.1007/s10156-013-0601-1. View